Private Capital Group’s Altimmune ALT Stock Holding History

Private Capital Group’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,153	Closed	-$13K	–	2077
2021 Q3	$13K	Buy	1,153 +560	+94%	+$6.81K	﹤0.01%	1239
2021 Q2	$6K	Buy	+593	New	+$8.11K	﹤0.01%	1499

Other funds holding ALT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Private Capital Group's ALT Position: Q4 2021 in Review

Private Capital Group sold out of Altimmune (ALT) in Q4 2021, closing a stake of 1,153 shares — an estimated $13K sold.

Private Capital Group first reported a position in ALT in Q2 2021 and held it in 2 quarters. The position peaked at $13K in Q3 2021. 102 funds tracked by Wall St. Rank hold ALT as of Q4 2021.

Private Capital Group reported no remaining Altimmune position as of Q4 2021 after selling out during the quarter.
Private Capital Group sold 1,153 Altimmune shares in Q4 2021, an estimated $13K.
Private Capital Group first reported a position in Altimmune in Q2 2021 and held it in 2 quarters.
Private Capital Group's Altimmune position peaked at $13K in Q3 2021.
102 funds tracked by Wall St. Rank held Altimmune as of Q4 2021.

Based on Private Capital Group's 13F filing for Q4 2021, filed 24 Jan 2022.